The mechanisms underlying the development of gastrointestinal (GI) damage by the NSAIDs differ considerably from drug to drug. Aside from environmental or intersubject influence (e.g., concurrent disease, physical or sociopsychologic stress, dietary and genetic status), the intrinsic pharmacokinetic and physicochemical differences in these drugs account for variations in their rate of absorption or uptake from the circulation into the GI mucosa. Differences in the preference for absorption in the direrent regions of the GI tract account for the propensity of these drugs to cause injury in those regions wherein they accumulate. Bacterial flora and food antigens may be particularly important in promoting injury in the lower intestinal tract, whereas in the sterile environment of the normal stomach these may have less significance (except in achlorhydric states).
INTRODUCTION
Gastrointestinal (GI) side effects from the nonsteroidal anti-inflammatory drugs (NSAIDs) constitute the most frequent of all the adverse reactions from this group of drugs (48). These reactions range in both severity and frequency from relatively mild, but nonetheless discomforting conditions such as epigastric pain, diarrhea and constipation to the more serious and potentially life-threatening states, namely GI ulceration and hemorrhage (40, 48). There are now indications that the site of these latter conditions in the GI tract may vary considerably with different NSAIDs (6, 20, 42). Likewise, the magnitude of mucosal damage leading to ulceration and hemorrhage varies with different drugs (38,40,47).
It is these two aspects which will be considered in some detail in this paper, together with a brief review of the current understanding of the mechanisms thought to be involved in the development of GI mucosal damage by the NSAIDs. Much of the evidence cited will be drawn from studies in laboratory animals, together with some evidence from observations in patients or volunteers. There are, unfortunately, few detailed studies that have explored the mechanisms of GI damage in man, because of the considerable ethical and technical problems in performing the kinds of invasive studies which are commonly performed in laboratory species.
While not wishing to ignore the importance of those less severe, but often very discomforting conditions such as abdominal pain, diarrhea, constipation, the fact is that relatively little is known about the factors underlying these states. GI pain fepresents symptomatic conditions which can only be explored in man; this makes it very difficult to be considered for detailed study. Thus, the main emphasis in this paper will be on the GI ulceration and hemorrhage caused by the NSAIDs.
INFLUENCE OF ENVIRONMENTAL AND

DISEASE STATES
It is now becoming apparent that a variety of environmental factors, as well as the disease state of the individual, contribute to the ulcerogenic actions of NSAIDs. Exposure to environmental conditions likely to induce stressful responses has, per se, long been considered as a factor responsible for TOXICOLOGIC PATHOLOGY the development of peptic and other ulcers in the upper GI tract (26) . Some individuals under stress may coincidentally smoke and consume alcohol to alleviate the symptoms of stress. Tobacco and alcohol are known to enhance acid and pepsin secretion in the stomach and are suspected to contribute or actually cause upper GI ulceration and bleeding in man (26) . The story of the involvement of these agents in the concept of the pathogenesis of upper GI ulceration in man may not be so simple. It is known that relatively high concentrations or quantities of alcohol (ethanol) actually cause gastric ulcers in laboratory animals (mostly rats) (6 1 ) . However, there is some indication that low to moderate alcohol ingestion in man may alleviate stress symptoms by enhancing blood flow in the stomach (a known protective mechanism against the actions of mucosal imtants), or by having relaxing effects on the central nervous system. Furthermore, the stimulation of acid and pepsin production by ganglionic stimulation from the nicotine in cigarettes does not necessarily mean that this is the sole factor in the upper GI ulceration seen with smokers. It is possible that the combination of ingested nicotine with the effects of stress in those individuals under psychological pressure who smoke could contribute to the development of ulcers.
If, therefore, an analysis is performed of the relative contributions of those factors which could be implicated in upper GI ulceration and hemorrhage in individuals who are suspected of not having ingested ulcerogenic NSAIDs, it is possible that this could be a complicated situation. This is because it is necessary to examine the interactions between the stress state (whatever nebulous factor in the environment which could be so defined) and the alcohol consumption and/or smoking. Evidence for this would.appear wanting, both from the point of view of analysis of data from clinical studies as well as from work in laboratory animals. It is, however, possible to obtain some indication from studies in laboratory animals of the likely interactions leading to gastric mucosal ulceration from combinations of NSAIDs with various stress states, ethanol, or nicotine (34-36, 38-40, 55, 59, 63) . In most of these studies it has been found that, with a few minor exceptions, the combination of an NSAID with one of the agents or states leads to a marked enhancement in gastric ulcerogenicity compared with that from either the NSAID, agent, or stress state alone. In many cases a synergy has been evident or suspect, though the quantitative responses may vary consistently with each type of drug and the agent or stressful state.
An examination of the mechanisms underlying interactions induced by' the combination of an NSAID with what could be regarded as an "accessory" agent or state (stressful conditions, alcohol, or nicotine) is far from complete, but already it is possible to identify some factors. From what is known of the pathogenesis of gastric ulcers induced by exposure to cold and/or restraint stress in rats, it is evident that a major factor contributing to the development of mucosal lesions is the combined interruption of blood flow and vascular injury (2) . Among the mucosal protective mechanisms presumed to be important in responding to stress and ulcerogenic agents, the maintenance or stimulation of mucosal blood flow by the endogenously produced prostaglandins (PGs) I2 and E2 predominates (18). Inhibition of the gastric mucosal production of these PGs by those NSAIDs with potent cyclooxygenase (CO) inhibitory effects is known to impair blood flow under some experimental conditions (2 l), and to cause vascular injury (53) in what can be defined as relatively "unstressed" animals.
Vascular injury and concomitant microcirculatory stasis is also considered to be involved in the pathogenesis of ethanol-induced injury (6 1 ) . This may result from direct injury to mucosal capillaries, as well as from the enhanced production of vasoactive leukotrienes (LTs) and PGs elicited by ethanol treatment (1 1) and production of oxyradicals. Moreover, the stimulation of acid and possibly pepsin(ogen) production by ethanol and nicotine may contribute to the ulcerogenic actions in the stomach of acidic NSAIDs, since these two physiological responses have been shown to play a role in gastric mucosal damage induced by drugs such as aspirin (49) . It is apparent, though, that the exact quantitative contribution of acidlpepsin secretion to the mucosal injury induced by many of the NSAIDs has yet to be defined quantitatively.
In addition to the above factors, the stress of arthritic disease may contribute to ulcer development initiated by the NSAIDs. Evidence for drug-disease interactions comes from studies in adjuvant-arthritic rats, where NSAIDs have been found to be appreciably more ulcerogenic in the gastric and ileojejunal mucosa than in normal (i.e., non-diseased) animals (59) . A number of factors could be responsible for the increased susceptibility of arthritic animals to the ulcerogenic effects of these drugs, including (a) defects in drug detoxifying activity in the liver and intestinal tract, (b) reduced mitochondria1 activity and possibly associated depression in GI mucosal ATP levels, (c) reduced synthesis of the protective mucus layer in the GI tract, and (d) reduction in the production of PGs (49) .
Having considered somewhat briefly the possible environmental and other extrinsic variables which appear to contribute to upper GI injury in man pri-marily attributed to the effects of NSAIDs, it is now appropriate to consider the actions of these antiinflammatory drugs themselves.
MECHANISMS OF GASTRIC MUCOSAL DAMAGE
Ulcerogenic Activities of NSAIDs. One of the central questions regarding the mechanisms of gastric injury by NSAIDs is: "Do aNNSAIDs exert thesaine extent of gastric ttlcerogenicity and, ifnot, why not?"
The simple answer to the first part ofthis question is that studies in both laboratory animals and humans show conclusively that NSAIDs do vary considerably in their potency as gastric ulcerogens (38, 40, 42, 47, 49). This statement requires qualification, for there are two essential precepts upon which the term potency can be applied. The first is the absolute ulcerogenic effects, i.e., graded on a molar or weight per kilogram body weight basis. The second, and indeed, important aspect from the therapeutic viewpoint, is the relationship of the absolute ulcerogenicity to the therapeutic potency ofthe drug. The term relative is applied here to mean the gastric ulcerogenic activity in relation to the anti-inflammatory effects in a range of acute or chronic test systems.
A number of studies have been performed comparing the gastric ulcerogenicity ofa range of NSAIDs with their anti-inflammatory effects in rodents (8, 33, 38,40,47). Some authors (8, 33) have claimed that there is a direct correlation between gastric ulcerogenicity and anti-inflammatory potency of NSAIDs regardless of their class, i.e., from a chemical viewpoint. The selection ofdata and application of statistical procedures employed in these studies has been criticized (43, and in 1 case (33) no valid statistical procedures were even employed.
Another approach (38, 40, 47) has been to recognize that, on the basis of there being marked variations in the chemical, pharmacokinetic, and biochemical properties of individual NSAIDs (44, 58), it is justifiable to segregate out those agents which differ from the standard ulcerogenic NSAIDs, such as aspirin, indomethacin and phenylbutazone, on the basis of their relative gastric ulcerogenicity. The results obtained from what might be regarded as a somewhat arbitrary system of segregation are, nonetheless, instructive. They show that in a range of test systems there are certain NSAIDs which are notably of lower relative ulcerogenicity than the abovementioned standard drugs (e.g., azapropazone, benoxaprofen, fenclofenac, oxaprozin, proquazone). There are a few, 'such as diclofenac and piroxicam which have a somewhat greater relative ulcerogenicity in a number ofthese test systems (38, 47). It should be noted that such comparisons are essentially specific to certain defined experimental variables. For example, the timing and frequency of dosage may be responsible for variations in the'pattern of gastric ulcerogenicity with a particular drug (11, 35, 39, 55, 59) . This feature is probably due largely to the rate of absorption and bio-availability in the mucosa from the systemic circulation (14,29,  49, 53) . Also, the ulcerogenic and the anti-inflammatory activities vary considerably according to the animal model system employed, i.e., type and degree of stress exposure, species, etc. (5 I).
With there being marked variations in the gastric ulcerogenicity of NSAIDs, the second part of the above question, concerning the reasons why there should be variations in the ulcerogenicity of different NSAIDs can be addressed. This is, of course, critical to the understanding of the mechanisms of NSAID injury in the stomach. Indeed, the fact that there is such a high degree of variation in the ulcerogenicity with different NSAIDs is very useful.
It enables the design of experiments in which drugs
with high ulcerogenic activity can be compared with those of lower ulcerogenicity so as to enable critical testing of hypotheses.
Inhibition of Prostaglandin Synthesis. The concept that inhibition of the production of PGs by NSAIDs could be related to the development of gastric mucosal damage was originally proposed by Main and Whittle (25) , based on Vane's studies on the PG synthesis inhibitory actions of these drugs (66). More recently, through an understanding of the actions of PGs on the gastric mucosa (4,'7, 16, 28, 37, 56, 68, 71), the concept has been extended to mean that the inhibition of PG synthesis by NSAIDs leads to a reduction in the endogenous "cytoprotection" provided by the PGs (19, 57) . The notion of "cytoprotection" has proven most controversial (37,63) as indeed the concept that NSAIDs exert their ulcerogenic effects solely through reducing the production of "cytoprotective" PGs (33). The evidence supporting the "cytoprotective" actions of the PGs indicates that these agents may in fact produce some of their actions through the nonspecific irritation of the upper surface of the gastric mucosa (62). Furthermore, there are other reactions that PGs elicit in the mucosa which may not necessarily be regardFd as a protection of the integrity of the cells of the gastric mucosa as implied by this term (7, 62) . Thus, the stimulation of blood flow, and the mucosal proliferative (hyperplastic?) reactions produced by the PGEs could certainly be regarded as being independent orthe direct actions of PGs on cellular integrity. As suggested by Szabo and Szelenyi (62), it is more appropriate to describe the protective effects of the PGs as being protective to the organ wherein this effect has been demonstrated. Possibly, the term "gastro-protection" as previously TOXICOLOGIC PATHOLOGY employed (54) would be more appropriate in the case of PG effects in the stomach.
The suggestion that NSAIDs cause their ulcerogenic effects by reducing the levels of endogenous gastroprotective PGs is really based on the experimental observation that the reduction in endogenoiis PGs produced by NSAIDs is corrected by exogenously-administered PGs. It is tacitly assumed that the effects of exogenously-administered PGs replicate those produced by the endogenous PGs. Since in many of the reported studies the PGs have been administered in doses which considerably exceed those measured in the gastric mucosa, it is likely that these observations represent pharmacologic effects of the PGs, and not simply a restoration of the depleted levels of PGs.
In support of the concept that PG synthesis inhibition is important in the development of NSAIDinduced gastric damage, some authors have claimed that there is a correlation between the gastro-ulcerogenic effects of NSAIDs and their inhibitory effects on the production of PGEz or PGI, (prostacyclin) (5, 9, 22) . Upon closer inspection of the statistical analyses in two of the reports (9,22), it is apparent that there is an element of selective treatment of the data which has not been adequately justified by the authors. Thus, a selection of the data provided by Dearden and Nicholson (9) was fitted to an equation of the general form:
where: PI,,, = log ICs0 for the inhibition of PG synthesis in vitro (system unspecified), and ID,o = dose required to produce an irritancy score of 10.
Using the reciprocal of the ID,, value is in a sense a statistical manipulation to achieve a tighter fit of scattered data, and in the absence ofdata on a simple linear model its use is really not adequately justified. Even so, however, the exclusion of data on aspirin and benoxaprofen just because they are outliers is questionable. It was also claimed that the data on benoxaprofen was excluded on the grounds of its relative lack of PG synthesis inhibitory effects (9). This reasoning is quite inaccurate, as data obtained from in vivo studies previously reported (43, 52) shows that benoxaprofen does indeed inhibit the production of PGs in vivo.
In the data of Krupp et a1 (22) , the values for aspirin stand alone and are solely responsible for the apparent correlation. Thus, it is apparent that the data reported on the statistical correlations are suspect, although there is no doubt that some kind of trend is evident in many of the published reports (5,9,22, 37) . A trend is one thing; a correlation has much more explicit meaning and implies more of a "cause and effect" relationship.
Another approach towards understanding of the relationship between inhibition of PG synthesis and the development of mucosal damage has involved studying the time course ofboth effects. Thus, Whittle (69) claimed that there was a "temporal" relationship between inhibition of PGI, production and the development of gastric mucosal lesions in the rat following the subcutaneous (sc) administration of indomethacin. Closer inspection of the data reveals that the times employed (3,24, and 48 hr) are, with the exception of the former, well beyond those which would be sensibly employed in a time course study having in mind the published data (14) showing an appreciable accumulation of the drug in the gastric mucosa up to 1 hr following sc administration of the drug. Furthermore, both this author and Ligumsky et a1 (23) showed that sc aspirin also reduced PGIz in the gastric mucosa, but failed to induce any visible signs of gastric mucosal injury. It should be noted that Ligumsky and co-workers employed much shorter times in their experiment and the results are, therefore, more relevant to the known pattern of the uptake of the drug by the sc route (30).
More recently, some other NSAIDs have been found to inhibit PG production without causinggastric mucosal injury in rats and pigs (49, 52, 53) . With some of the drugs a contrary situation was observed, even though appreciable mucosal absorption of the drugs could be demonstrated (49, 52,  5 3) .
These studies show that the inhibition of PG production by NSAIDs in the gastric mucosa can occur independent of the development of lesions. How, then, can these results be reconciled with data showing that the rank order of PG synthesis inhibition by NSAIDs roughly correlates with their gastric ulcerogenicity? It is suggested that possibly the reduction in PGs caused by potent CO inhibitors may lead to a type of "priming" response which could be envisaged as a weakening in mucosal defenses. Following this, other effects of the drugs together with the influences of stress or disease, cause additional weakening of the mucosal defenses, leading to the full expression of the ulcerogenicity of NSAIDs. Some indication of the influence of primihg effects of PG inhibition by NSAIDs whose ulcerogenic effects are more fully expressed by secondary (e.g., stress) effects is seen with drugs that normally exhibit low ulcerogenicity, such as azapropazone and oxaprozin. These can inhibit PGE production in the stomach of rats without causing mucosal injury (49). However, when mice given these drugs orally are also given a cholinomimetic agent to stimulate gastric mucosal acid and pepsin production, or when these drugs are given to stressed stomach (4, 7, 16,28, 37,46, 56, 68, 71 ). The vascular injury and consequent extravasation of blood components into the interstitial space adjacent to the lamina propria could be aided by the druginduced inhibition of platelet aggregation. animals, the ulcerogenic effects of the NSAIDs are revealed (47). Likewise, this cryptic gastro-ulcerogenicity of these and otherwise apparently non-ulcerogenic NSAIDs is revealed in animals in whom chronic inflammatory insult has been induced (35, 39, 55, 59) .
Lipoxygenase Pathway Activation and Oxyradicals. Another consequence of the inhibition by
NSAIDs of the PG cyclo-oxygenase pathway, aside from reducing the levels of gastro-protective PGs, is that it could lead to a diversion of arachidonate through to the 5-(and possibly other) lipoxygenase (LO) pathways ( Fig. 1) (46) . This can be envisaged as having the consequences of producing appreciable quantities of leukotrienes (LTs), hydroperoxyeicosatetraenoic acids (HPETEs), and active oxygen TOXICOLOGIC PATHOLOGY radicals (Omx, OH'), which could affect mucosal integrity by enhancing vasoactive responses, reducing mucosal electropotential difference, and stimulating pepsin production ( Fig. 1) (46) . Normally, the gastric mucosa does not produce any detectable LO products (10, 52), but after immunological stimulation (10) or ethanol treatment (1 l), appreciable quantities of LTs and other LO products are produced. It has been postulated (46) that in the normal mucosa or possibly under some conditions (acid/ pepsin stimulation, disease, or physical stress states), CO inhibition by NSAIDs could lead to diversion of arachidonate through the LO pathway, which could lead to the abovementioned responses in the mucosa. In support of this suggestion, recent studies have shown that administration of LT antagonists or 5-LO inhibitors markedly reduces the gastric ulcerogenicity of indomethacin and other NSAIDs in mice treated with the cholinomimetic, bethanechol chloride (46). This evidence, combined with observations that 1) dual CO-LO inhibitors cause less gastric mucosal damage than CO inhibitors of equal anti-inflammatory potency (1 3,47, 70), and 2) that antioxidants (e.g., butyl hydroxytoluene) which scavenge oxygen radicals can inhibit gastric lesions induced in rats by CO inhibitors (43, 67) , suggests that the diversion of arachidonic acid by the inhibition of CO by NSAIDs could have dual consequences. Hence, there could be effects from the relative excess of LO products produced from this inhibition of CO activity as well as loss of endogenous gastroprotective capacity from the deficit of PGs. Antioxidants and dual inhibitors, such as BW-755c, may also have alternative effects including scavenging of hydroxylradicals and superoxide anions or from the stimulation of alkaline secretion (1 3), so these drug actions could have effects in addition to influences on the LO pathway of arachidonate metabolism.
Mircics and Bicarbonate Secretion. A number of studies have shown the importance of the mucus layer and ancillary secretion of bicarbonate for the defense of the gastric and duodenal mucosa (1 , 4 1). Furthermore, NSAIDs have been shown to reduce these protective secretions (1) . Loss ofthe protection of the mucosa occurs from the physical effects of these drugs in reducing the adherent mucus layer (1 , 41) which serves as a barrier to the diffusion of acid. This reduction in mucus can also be caused by inhibition of the biosynthesis of mucus glycoproteins (1) . More recently, Hills and co-workers (7) have shown that aspirin and ethanol markedly reduce the hydrophobicity of the mucosal membranes, which they ascribe to the phospholipid layer on the mucosal surface.
PGs have a role in regulating mucus secretion (1 , 41); thus, reduced PG production might be responsible for the reduction in mucus by NSAIDs. However, it has also been shown that NSAIDs directly inhibit the enzymes involved in the biosynthesis of mucus (41), so both PG-dependent and PG-independent mechanisms appear to be contributing to effects of NSAIDs on mucus production.
Other Miicosal Defertses Afected by NSAIDs. A number of other mucosal defensive reactions affected by NSAIDs could be important in the pathogenesis of mucosal injury by these agents. These have been reviewed recently (49) and include: a) the regulation of nucleotide synthesis and breakdown (3, 3 1 , 60); b) the metabolism of glucose and production of energy-yielding intermediates such as ATP (12,27,44); c) PG-receptor mediated changes induced by the drugs, possibly involving alteration in intracellular second messenger functions (64); d) calcium ion channels and intracellular regulation of this ion (1 5); and e) dopamine and probably other central neuronal pathways regulating gastric motility and other functions (24, 32) .
CONCLUSIONS
It has become apparent in recent years that the simple concept originally proposed during the early 1970s, that NSAIDs cause gastric mucosal damage by inhibiting the synthesis of prostaglandins, is very much an over-simplification of the real situation. More complex biochemical changes are evident, and the propensity of an NSAID to induce damage will depend on the relative rates of gastric absorption and systemic availability to the mucosa ofdrug from the circulation, and the extent to which the drug affects all the different mucosal defensive processes.
